

CENTRAL NERVOUS SYSTEM ACTIVITY OF ARGYREIA SPECIOSA

Vyawahare Neeraj S*¹, Pujari Rohini R¹, Kagathara Virendra G¹, Gangurde Prajakta R¹ Bodhankar Subhash L² and Hadambar Avinash A¹

1. Department of Pharmacology, AISSMS College of Pharmacy, Kennedy Road, Pune-411 001, India. Tel: +91-20-26058204 (Ext-43), Fax: +91-20-26058208

2. Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune-411 038, India.

Received on : 14.03.2009

Revised : 17.07.09

Accepted : 22.07.09

ABSTRACT

Argyreia speciosa (AS), a long woody climber is commonly known as Vryddhadaru in Sanskrit. It is distributed throughout India upto altitude of 300 m. It is scientifically documented for its antiinflammatory, antiarthritic, immunomodulatory, antistress and aphrodisiac activities. The roots and seeds are used as restorative in various nervous system disorders. The roots are also reported to possess nootropic, antimicrobial, diuretic properties and used in chronic peptic ulcer, gonorrhoea and rheumatism. In the present study the central nervous system (CNS) activity of the hydroalcoholic extract of *Argyreia speciosa* roots at different doses (100, 200, 400 mg/kg) was studied using various standard paradigms. The results revealed that the *Argyreia speciosa* extract significantly increased discrimination index in object recognition test, reduced 5HTP induced head twiches, potentiated haloperidol induced catalepsy, delayed the onset of pentylenetetrazole induced convulsions and antagonised amphetamine induced motor hyperactivity.

Keywords: *Argyreia speciosa*; anxiety; cognition; convulsions; locomotor activity.

INTRODUCTION

Argyreia speciosa an elephant creeper, a long woody climber found throughout India is commonly used in local folk medical practices in India¹. It is traditionally used in gonorrhoea, strangury and chronic peptic ulcers. The leaves are used externally in skin diseases such as ringworm, eczema, itch and internally to cure boils, swellings etc². The leaves are also employed as rubefacient and local stimulant. The seeds are reported to be potent antihypertensive and spasmolytic. The roots are indigenously prescribed as an aphrodisiac, diuretic and antirheumatic. The roots are also claimed to be a tonic in disorders of central nervous system^{2,3}. Phytochemically the whole plant contains alkaloids, flavone glycosides, flavonoids steroids, triterpenoids and lipids³. Various alkaloids such from the plant namely friedelin, chanaclavine I, II, ergine, agroclavine, ergonovine, ergometrinine, ergometrine, isoergine lysergol, isolysergol, penniclavine, chanclavine, molliclavine, steoclavine have been isolated from the plant³⁻⁵. It also contains flavone glycosides and flavonoids such as quercetin and kaempferol⁴, along with some steroids, triterpenoids, lipids and other phytochemicals such as scopoletin, hexadecanyl p-hydroxycinnamate⁵. Despite the extensive phytochemical work on *Argyreia speciosa*, there is paucity of reports on the pharmacological properties, especially CNS effects of the plant.

The alcoholic and aqueous leaf extracts of *Argyreia speciosa* are documented for their dose dependant pregnancy interruption action in rats at early stages of

pregnancy⁶. Another study has revealed the dose dependent potentiation of delayed type of hypersensitivity reaction by the plant, mediated by enhanced production of circulating antibody titre⁷. It has also been shown that the ethanolic extract of its roots produced anti-inflammatory and antiarthritic effect in carrageenan and Freund's complete adjuvant model respectively⁸. Leaves have been documented for its antidiabetic potential⁹.

Vyawahare NS *et al* have documented the nootropic effect of *Argyreia speciosa*, however the possible mechanism of its action has not been yet revealed¹⁰. It is well established that the nootropic activity is associated with modulation of various neurotransmitters that can be gauged by either studying the effect on generalised neuropharmacological behavior or by direct estimation of neurotransmitters¹¹. Looking at the complexity of CNS and its transmission it is usually recommended to study neuropharmacological evaluation followed by direct neurochemical evaluation.

In light of the fact that *Argyreia speciosa* has traditionally been used in cases of nervous disorders, the present study titled "Central nervous system activity of *Argyreia speciosa*" was undertaken.

MATERIALS AND METHODS**Plant material**

The hydroalcoholic extract of roots of AS prepared by the following procedure was received as gift sample (ARG-4019) from Green Chem, Bangalore, India.

*Correspondence : neerajsv@rediffmail.com

Preparation of extract

Roots were extracted with 50% aqueous alcohol and concentrated. The concentrated mass was washed with petroleum ether several times to remove the resinous matter. Then the mass was diluted with 25% aqueous alcohol, filtered and concentrated, dried to get the powdered form of the extract.

Chemicals and drugs

Pentylentetrazole, haloperidol, amphetamine, 5HTP, (Rajesh chemicals, Mumbai) and sodium nitrate, (Loba chemicals, Mumbai) were purchased from respective vendors. Diazepam (Calmose) and Pentazocin injection (Fortwin), Piracetam suspension (Nootropil), Clonazepam (Clonotril) and Phenytoin (Eptoin) tablets were purchased from the local market.

Preparation of drug solution

Accurately weighed quantity of powdered extract was dissolved in the distilled water to prepare the appropriate stock solution of the drug i.e. 10 mg/ml, 20 mg/ml and 40 mg/ml respectively. The doses were administered orally by selecting the appropriate concentration of the stock solution. Clonazepam and Phenytoin were suspended in 1% w/v acacia.

Animals

Swiss male albino mice (18-22g) were used. They were maintained at $25 \pm 2^\circ$ C and relative humidity of 45 to 55% and under standard environmental conditions (12 hrs light 12 hrs dark cycle). The animals had free access to food (Chakan Oil Mills, Pune, India) and water *ad libitum*. Institutional Animal Ethical Committee (IAEC) approved the protocol. All experiments were carried out between 12:00-16:00 hrs.

Acute toxicity test

Healthy adult male albino mice (18-22 g) were subjected to acute toxicity studies as per guidelines (AOT 425) suggested by the organization for economic co-operation and development (OECD-2001). The mice were observed continuously for 2 hrs for behavioral and autonomic profiles and for any sign of toxicity or mortality up to a period of seven days¹².

EXPERIMENTAL DESIGN**Behavioral effects**

Behavioral changes of AS (100, 200 and 400 mg/kg) were assessed by visual observation 60 min after administration of vehicle or AS for next 2 hrs. The observation parameters consisted of body position, alertness, reactivity to touch stimuli, righting reflex and lacrimation¹³.

Effect on motor coordination

The motor coordination was assessed using digital rota rod (Inco - Ambala, India). Mice were trained by placing them on a rotating rod (20 rev/min), twice daily for three consecutive days before the experiment. 30 min interval

was kept between two trials. Only those mice which have demonstrated their ability to remain on the rotating rod for at least 2 min were selected. These selected mice were divided into five groups with 6 animals in each group. The mice were then tested for motor coordination to record basal fall off time followed by respective drug treatment. One hour following the administration of vehicle or drug, mice were placed again on the rotating rod and the fall off time per 300 sec was recorded. The difference between mean fall off time before and after drug treatment was considered for evaluation. Diazepam (2 mg/kg, i.p.) was used as a reference standard^{14,15}.

Locomotor activity

The locomotor activity (horizontal activity) was measured using a digital actophotometer (Space-lab, India). Each mouse was placed individually in the actophotometer for 5 min and basal activity score was obtained. Subsequently animals were divided into five groups and treated with test drugs. 60 min. after dosing, the mice were placed again in the actophotometer for recording the activity score as described earlier. The results were reported as mean change in the locomotor activity. Diazepam (2 mg/kg, i p) preparation was used as reference standard¹⁶.

Analgesic activity

The analgesic effect was studied using digital hot plate (Columbus - USA) method wherein the reaction time (paw licking, jumping or any other sign of discomfort) was recorded at 0, 60, and 120 min after administration of vehicle (10 ml/kg) or AS extract (100, 200 and 400 mg/kg). The temperature of the plate was maintained at $55^\circ\text{C} \pm 01^\circ$ C. A cut off reaction time of 30 sec was chosen in order to avoid injury. Pentazocin (30 mg/kg, s.c.) was used as a reference standard¹⁷.

Elevated plus maze (EPM)

An Elevated plus maze (V. J. Instruments, India) consisting of two open arms (35×6 cm) and two enclosed arms (35 × 6 × 15 cm) was used. The maze was elevated to the height of 40 cm. Mice were placed individually in the center of the EPM facing an enclosed arm. The time spent by the mouse during the next 05 min on the open and enclosed arm was recorded. The animals received vehicle (10 ml/kg) or AS (100, 200 and 400 mg/kg) 60 min before and diazepam (1 mg/kg, i.p.) 30 min before their placement on the maze. Increased exploratory activity in the open arm was taken as an indication of anxiolytic activity^{18,19}.

Object recognition test

The apparatus consisted of white colored plywood (70×60×30 cm) with a grid floor. It was illuminated by a 40 W lamp suspended 50 cm above the apparatus. The object to be discriminated was also made of

plywood in two different shapes of 10 cm height and colored black.

One day before the test, mice were allowed to explore the box without any object for 2 min. On the day of test, in the first trial (T1) conducted 60 min after administration of vehicle (10 ml/kg) or AS (100, 200, 400 mg/kg) or piracetam (150 mg/kg) two identical objects were presented in opposite corners of the box and the time taken by each mouse to complete 20 sec of object exploration was recorded (Exploration was considered as directing the nose at a distance less than 2 cm to the object and/or touching with nose).

Second trial (T2) was performed 90 min after first (T1) and a new object replaced one of the objects presented in T1 and mice were left in the box for next 5 min. The time spent for exploring the familiar (F) and the new object (N) was recorded separately and discrimination index (D) was calculated as $(N-F)/(N+F)$. The object was changed randomly and apparatus was cleaned with hydrogen peroxide after each trial to avoid place preference and the influence of olfactory stimuli respectively²⁰.

Double unit Mirrored chamber

The mirrored chamber apparatus fabricated locally consisted of a mirrored cube (30×30×30 cm), open on one side and placed in square box. The container box (40×40×30 cm) has a white floor and black wall making 5 cm corridor completely surrounding the mirrored chamber. A sixth mirror was placed on the wall of the box, positioned to face the open side of the mirror chamber. The latency to enter the mirror chamber and time spent in mirror chamber during 5 min observation period was recorded 60 min after the drug administration. Diazepam (1mg/kg, i.p) was used as a reference standard. These mice were not exposed to the apparatus before the test and evaluated only once to avoid habituation problem. The apparatus was washed after each evaluation to eliminate potential cues such excreta, urine left by the previous occupant^{21,22}.

5HTP-induced head twitches

Mice were pretreated with pargyline (75 mg/kg, i.p) in order to prevent the rapid degradation of 5-HTP. Thirty minutes later, vehicle or AS was administered. 60 min thereafter, 5-HTP (50 mg/kg, i.p.) was injected in the mice and head twitches were counted for ten minutes after the onset of head twitches²³⁻²⁵.

Haloperidol induced catalepsy

Mice were divided into four groups. The control group received vehicle (10 ml/kg, p.o.) whereas the other group received AS (100, 200 and 400 mg/kg) 60 min before haloperidol (1 mg/kg, i.p). After the treatment, the forepaws of the mice were placed on rod of 0.9 cm diameter set at 2.5 cm from top. Duration for which the mice retains the forepaws on the elevated rod was noted down at 0, 15, 30, 60, 90 and 120 min. the cut off time was 300 sec. The animals were tested twice at

each time interval and only the greater duration of time was recorded. Between measurements, the mice were returned to their home cages^{26,27}.

Sodium nitrite induced respiratory arrest

Mice were divided into four groups and were treated with vehicle (10 ml/kg) or AS (100, 200, 400mg/kg). Sixty min later, all mice were subjected to sodium nitrite treatment (250 mg/kg, i.p). The time between injection of sodium nitrite and death was recorded²⁸.

Amphetamine antagonism

Mice were divided in four groups and treated with either vehicle or AS. 60 min later all animals received amphetamine (1 mg/kg, i.p.) and 30 min thereafter, the locomotor activity was measured for 5 min duration using digital actophotometer²⁹.

Clonidine induced hypothermia

Mice were taken in groups of six each and rectal temperature was recorded using digital telethermometer (Dolphin, India) every 60 min after clonidine (0.1 mg/kg, i.p.) till 180 min. vehicle (10 ml/kg) or AS (100, 200 and 400 mg/kg) were administered 60 min before clonidine³⁰.

Pentylentetrazole induced seizure (PTZ)

Clonic seizures were induced 60 min after respective drug treatment in mice by subcutaneous injection of 80mg/kg pentylentetrazole. The latency to the onset of seizures in non-protected mice and lethality during the following 24 h was recorded and compared with those of control mice to assess the anticonvulsant activity of the extract. Clonazepam (0.1mg/kg, i.p.) was used as a reference standard³¹⁻³³.

Maximal electroshock induced seizures (MES)

Tonic clonic convulsions were induced 60 min after the respective drug treatment by giving maximal electroshock seizures (MES) (40mA for 0.2sec) using an electroconvulsimeter (INCO, Ambala, India) via crocodile ear clip 60 min after administration of either vehicle(10 ml/kg) , AS (100, 200 and 400 mg/kg) or Phenytoin (20 mg/kg, i.p). The number of animals protected from tonic hind limb extension seizure (abolition of tonic hind limb extension within 10 sec after delivery of the electroshock was considered as protected mice.) and duration of tonic hind limb extension seizure was determined in each dose group^{31,34}.

Statistical analysis

The results are expressed as mean \pm SEM. Comparison between the groups were made by one way analysis of variance (ANOVA) followed by Dunnett's test.

RESULTS

Acute oral toxicity test

All mice were free of any toxicity as per acceptable range given by the OECD guidelines up to the dose of

2000 mg/kg. From this data and pilot study reports; three different doses 100, 200, 400 mg/kg were selected for further study.

Behavioral assessment

The mice were observed for a period of 2 hr; 60 min after oral administration of vehicle or AS (100, 200, 400 mg/kg). The observations are summarised in Table 1.

Table 1. Behavioral assessment of AS extract in mice behavioral signs.

Behavioral signs	Vehicle (10ml/kg)	AS (100 mg/kg)	AS (200 mg/kg)	AS (400 mg/kg)
Alertness	-	-	?	?
Body position	-	-	-	-
Reactivity to touch stimuli	-	-	-	-
Righting reflex	-	-	-	-
Lacrimation	-	-	-	-

- : Normal, '□': Increased, '▣': Decreased.

Effect on motor coordination

All the doses of AS (100, 200, 400 mg/kg) were found to be statistically insignificant towards the mean fall off time while diazepam (2 mg/kg, i.p) showed a significant reduction (P<0.01) in fall off time recorded as mean change in fall off time (Fig 1).




Fig. 1. Effect of AS extract and diazepam on motor coordination in mice. n=6, Data analysed by ANOVA followed by Dunnetts test. **P<0.01.

Effect on Locomotor activity

None of the doses of AS (100, 200, 400 mg/kg) showed any significant alteration in locomotion. Diazepam 2 mg/kg significantly (P<0.01) reduced the locomotor activity (Fig. 2).




Fig. 2. Effect of AS extract and diazepam on motor performance in mice. n=6, Data analysed by ANOVA followed by Dunnetts test. **P<0.01

Analgesic activity

The reaction time in mice treated with different doses of AS (100, 200, 400 mg/kg), recorded at 0, 60 and 120 min did not show significant change when compared against vehicle treated mice. Pentazocin (30 mg/kg) was found to be effective in this regard (Data not shown).

Elevated plus maze

The time spent in open and enclosed arm by vehicle treated control mice were 67.36 ± 4.01 sec and 219.56 ± 8.11 sec respectively. Diazepam (1mg/kg, i.p) significantly increased (P<0.01) time spent in open arm and thereby showed anxiolytic action while AS treatment did not show any significant effect on the time spent in open or enclosed arm by mice when placed on EPM. (Table 2).

Table 2: Effect of AS extract and diazepam on anxiety induced using elevated plus maze apparatus.

Treatment (mg/kg)	Time spent in second (mean±SEM)	
	Open arm	Enclosed arm
Vehicle (10ml/kg)	67.36 ± 4.01	219.56 ± 8.11
AS (100 mg/kg)	73.24 ± 4.53	210.92 ± 4.55
AS (200 mg/kg)	70.92 ± 5.76	213.31 ± 6.52
AS (400 mg/kg)	75.35 ± 4.66	206.37 ± 4.06
Diazepam (1 mg/kg)	100.11 ± 4.02**	189.99 ± 3.05**

n = 6 Data analyzed by one-way ANOVA followed by Dunnett's test. **P<0.01.

Object recognition test

In this test, AS (200 and 400mg/kg) and piracetam (150 mg/kg) treated mice required significantly less time against control mice to explore the familiar objects as compared with the new object and thus significantly improved the discrimination index. The AS 400 mg/kg was found to be more significant (P<0.01) than AS 200 mg/kg (P<0.05) (Fig 3).




Fig. 3. Effect of AS extract and piracetam on discrimination index in object recognition test in mice. n=6, Data analysed by one way ANOVA followed by Dunnetts test. *P<0.05, **P<0.01

Double unit mirrored chamber

Pre treatment with different doses of AS did not affect latency to first entry or time spent in mirror chamber when compared to vehicle treated mice. Diazepam (1 mg/kg, i.p), a reference standard significantly increased the time spent (P<0.01) and

latency to the first entry ($P < 0.05$) in mirror chamber and thereby showed significant anxiolytic effect (Data not shown).

5HTP-induced head twitches in mice

5 HTP induced 15.40 ± 1.43 head twitches in 10 minutes in vehicle treated control mice. Pretreatment with AS (100, 200 400 mg/kg) significantly reduced the number of head twitches when compared to the control values. AS 100 mg/kg was found to be less effective ($P < 0.05$) than AS 200 and 400 mg/kg ($P < 0.01$) (Fig 4).




Fig. 4. Effect of AS extract on number of head twitches induced by 5HTP in mice
 $n = 5$, Data was analysed by one way analysis of variance (ANOVA) followed by Dunnett's test. * $P < 0.05$, ** $P < 0.01$.

Haloperidol induced catalepsy

In haloperidol-induced catalepsy, maximum catalepsy was noted at 120 min. AS 200 and 400 mg/kg showed a significant ($P < 0.01$) increase in the duration of catalepsy from 90 min to 120 min while AS 100 mg/kg reported a significant increase in duration of catalepsy ($P < 0.05$) at 120 minute only (Table 3).

Table 3: Effect of AS on duration of haloperidol induced catalepsy in mice.

Time	Mean duration of catalepsy in seconds			
	Vehicle	AS(100 mg/kg)	AS(200 mg/kg)	AS(400 mg/kg)
0 min	3.75 ± 0.14	3.85 ± 0.12	3.91 ± 0.08	3.87 ± 0.13
15 min	17.42 ± 0.87	18.61 ± 0.70	19.87 ± 1.05	18.93 ± 0.63
30 min	31.33 ± 1.50	32.50 ± 1.82	33.78 ± 1.99	36.83 ± 1.74
60 min	150.50 ± 4.21	150.56 ± 3.38	157.41 ± 2.49	160.90 ± 2.88
90 min	209.54 ± 2.57	214.76 ± 3.43	248.62** ± 3.15	252.71** ± 2.83
120 min	252.79 ± 3.58	262.98* ± 2.94	265.32** ± 2.19	266.13** ± 4.88

$n=6$, Data was analyzed by one-way ANOVA followed by Dunnett's test. * $P < 0.05$, ** $P < 0.01$.

Sodium nitrite induced respiratory arrest

None of the doses of AS (100, 200, 400 mg/kg) significantly altered the onset of respiratory arrest (Fig 5).

Amphetamine antagonism

AS 100, 200 and 400 mg/kg showed significant reduction in amphetamine induced increased locomotor activity score. The dose of 100 mg/kg was found to be less effective ($P < 0.05$) than the subsequent two doses (200 and 400 mg/kg) of AS ($P < 0.01$) (Fig 6).




Fig. 5. Effect of AS extract on the onset of respiratory arrest induced by sodium nitrite in mice.
 $n = 6$, Data was analysed by one way analysis of variance (ANOVA) followed by Dunnett's test..




Fig. 6. Effect of AS extract on the amphetamine antagonism in mice.
 $n=6$, Data was analysed by one way analysis of variance (ANOVA) followed by Dunnett's test. * $P < 0.05$, ** $P < 0.01$.

Clonidine induced hypothermia

Clonidine induced hypothermia was not affected by the pre treatment of AS. However, a non significant potentiation of hypothermic effect was seen (Data not shown).

Pentylenetetrazole induced seizure (PTZ)

In vehicle treated control mice, convulsions were produced after 191.50 ± 6.22 sec. The pretreatment with AS (200 and 400 mg/kg) delayed this onset up to 219.50 ± 6.74 sec and 218.33 ± 4.61 sec respectively, thus showed significant delay ($P < 0.05$) in the onset of the first clonus. Also, AS 400 mg/kg treatment showed survival of one mouse while standard clonazepam showed 100% protection (Table 4).

Table 4: Effect of AS extract and clonazepam on Pentylenetetrazole induced convulsions in mice.

Treatment (mg/kg)	Onset of first clonus (second)	No. of mice survived/mice used	Percent mortality (%)
Control	191.50 ± 6.22	0/6	100 %
AS 100	207.16 ± 8.49	0/6	100 %
AS 200	219.50 ± 6.74*	0/6	100 %
AS 400	218.33 ± 4.61*	1/6	83.33 %
Clonazepam 0.1	Nil	6/6	0.00 %

$n=6$, Data was analyzed by one-way ANOVA followed by Dunnett's test. * $P < 0.05$.

Maximal electroshock induced seizures (MES)

All the doses of AS failed to prevent tonic hind limb extension (THLE), however a non significant reduction in duration of THLE was observed. Phenytoin showed 100% protection in this regard (Table 5).

Table 5: Effect of AS extract and phenytoin on mes induced convulsions in mice.

Treatment (mg/kg)	Duration of hind limb extension (second)	Mice convulsed/mice used
Vehicle	23.67 ± 1.85	6/6
AS (100)	20.33 ± 1.49	6/6
AS (200)	19.20 ± 1.00	6/6
AS (400)	19.96 ± 1.03	6/6
Phenytoin (25)	Nil	0/6

n=6 Data was analyzed by one-way ANOVA followed by Dunnett's.

DISCUSSION

The present study investigated the putative central effect of the hydroalcoholic extract of roots of *Argyreia speciosa*, a plant used in Indian traditional system of medicine. The study provided data on the effects of AS on the central nervous system that is useful to explore possible mechanism of its nootropic action.

The object recognition test is widely accepted model to assess facilitation of learning and memory process in absence of cognitive deficit³⁵. The single dose oral administration of AS showed significant improvement in discrimination index and thereby supported the traditional claim. The results also suggest possible use of extract in slow learners wherein cognitive deficit is not reported.

The rota rod and actophotometer were used to assess the motor co-ordination and locomotor activity respectively. Performance observed in mice treated with AS was similar in relation to the control group suggesting absence of impaired motor co-ordination and locomotion due to the AS treatment. Absence of motor activity was also observed in elevated plus maze and double unit mirror chamber, where AS treated mice performed similarly to the control mice. In this way, we can accept absence of deleterious effect of AS on motor activity and co-ordination^{36,37}. Thus AS meet major criterion of the drug that acts on CNS. The absence of anxiolytic activity screened using elevated plus maze and double unit mirrored chamber can be helpful to boost nootropic activity because many anxiolytic agents used in current pharmacotherapy have shown adverse effects on learning and memory processes suggesting inverse relationship between anxiety and cognition³⁸.

The 5HTP induced head twitches are due to increase in serotonin levels in CNS³⁹. The AS treatment significantly reduced head twitches and thereby suggested reduction in central serotonergic transmission. The increase in serotonin level has been reported to interfere with learning acquisition and memory consolidation⁴⁰⁻⁴². The above mentioned results of head twitches point out the possible role of reduced serotonergic transmission in the nootropic action of AS and thereby support the previous findings.

Noradrenergic transmission has been reported to play diverse role in the cognition. The augmentation as well as retardation of its transmission has been linked with the process of cognition⁴³. AS extract demonstrated significant antagonism of amphetamine induced hyperactivity which may be due to either its antidopaminergic or antiadrenergic action^{43,44}. On the

contrary, AS treatment significantly facilitated haloperidol induced catalepsy that appears to be due to blockade of dopamine transmission suggesting antidopaminergic activity by the extract⁴⁵. Moreover, clonidine induced hypothermia was not significantly antagonised by the extract which further postulated the inhibition of noradrenergic transmission by the extract⁴⁶. Sodium nitrite induced respiratory arrest is widely accepted indirect method to check involvement of cholinergic transmission⁴⁷. The AS pretreatment did not inhibit the effect of sodium nitrite suggesting mechanism devoid of cholinergic transmission. Although cholinergic transmission play vital role in cognition but earlier studies have also documented nootropic activity without any modulation in the cholinergic neurotransmission⁴⁸⁻⁵⁰.

The anticonvulsant activity evaluated against PTZ and MES induced convulsions using widely accepted methods with high predictive value for detection of clinically effective drugs revealed effectiveness of the extract towards PTZ model only⁵¹. PTZ test identifies drugs with efficacy against non convulsive absence or myoclonic seizures due to increase of the seizure threshold while the MES test identifies agent active against generalised tonic-clonic seizures due to blocking of seizure spread⁵². The AS was able to modify the progress of convulsive episodes induced by PTZ and thereby suggest possible use of the extract in the treatment of absence seizures. In addition, it can be ideal option to control the cognitive deficit associated with convulsion and post convulsive cognitive deficit.

CONCLUSION

In conclusion, the study provides evidence that the hydroalcoholic extract of the roots of AS possess significant nootropic activity which is not accompanied by motor incoordination. The study further revealed that inhibition of dopaminergic, serotonergic as well as noradrenergic transmission could be the possible mechanism of action. However, further studies involving direct neurochemical estimations are necessary to confirm and extend these results.

ACKNOWLEDGEMENTS

The authors are grateful to Mr. Rajendran, Green Chem. Bangalore, India, for providing gift sample of hydroalcoholic extract of *Argyreia speciosa*. Principal Dr. D. M. Sakarkar, S.N. Institute of Pharmacy, Pusad and Dr. K. G. Bothara, Principal AISSMS College of Pharmacy, Pune for providing the necessary support.

REFERENCES

1. Kirtikar KR and Basu BD. In *Indian Medicinal Plants*. Dehradun: Oriental Enterprises 2001, p1706.
2. Chopra RN, Nayar SL and Chopra IC. In *Glossary of Indian Medicinal Plants*. New Delhi: Council of Scientific and Industrial Research (CSIR) 1965, p24.

3. Anonymus In *The Wealth of India (A dictionary of Indian raw materials and industrial products) Raw materials*. New Delhi: CSIR 1985, p418.
4. Srivastava A, et al. *Ind J Chem*. 1998; 37B:192.
5. Shukla YN, et al. *J Ethnopharmacol*. 1999; 67:241.
6. Satyanarayana T, et al. *Phcog Mag*. 2008; 4(15):51.
7. Gokhale AB, et al. *J Ethanopharmacol*. 2003; 84:109.
8. Gokhale AB, et al. *Phytomedicine*. 2002; 9: 433.
9. Chao JM, et al. *J Pharm Sci*. 1973 ;12:2435.
10. Vyawahare NS, et al. *Phcog Mag*. 2009;4(17): 43.
11. Decker MW, et al. *Synapse*. 1991; 7:151.
12. OECD Guideline For The Testing of Chemicals: Guidance document on acute oral toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment 2000.
13. Taber RI, et al. *Psychopharmacologia*. 1968;12: 441.
14. Umukoro S, et al. *J Nat Rem*. 2005; 5/2:141.
15. Kulkarni SK, et al. *Indian Drugs*. 1997; 35: 536.
16. Turner RA. In *Screening procedure in Pharmacology*. New York: Academic press 1972, p78.
17. Gupta M, et al. *Fitoterapia*. 1999; 70: 244.
18. Kulkarni SK, et al. *Ind J Expt Boil*. 1993; 31: 435.
19. Lister RG. *Psychopharmacology*. 1987; 92: 180.
20. Bartolini L, et al. *Pharmacol Biochem Behav*. 1996; 53: 277.
21. Kulkarni SK. In *Hand book of experimental Pharmacology* New Delhi: Vallabh Prakashan 2005, p 137.
22. Bhattacharya SK, et al. *Ind J Expt Boil*. 1997; 35: 565.
23. Arulmozi DK, et al. *Ind J Pharmacol*. 2005; 35(2): 120.
24. Chung IW, et al. *Pharmacol Biochem Behav*. 2002; 71: 191.
25. Corne SJ, et al. *Br J Pharmacol*. 1963; 20: 106.
26. Feere S, et al. *Pharmacol Biochem Behav*. 1990; 35: 735.
27. Khisti RT, et al. *Neuroscience letter*. 1998; 251: 1.
28. Elsner N and Heisenberg M. In *Effect of cromakalin on sodium nitrite intoxication*. Hock FJ, eds. Proceeding of 21st Gottingen Neurobiology Conference, Stuttgart:George Thieme Verlag 1993, p681.
29. Achliya GS, et al. *Ind J Pharmacol*. 2005; 37(1): 33.
30. Drew GM, et al. *Br J Pharmacol*. 1997; 63: 468.
31. Swinyard EA and Woodhead JH. In *Anti-epileptic drugs*. Woodburg DH, Penry JK, Pippenger CE, eds. New York : Raven Press 1982, p111.
32. Bienvenu E, et al. *Phytomedicine*. 2002; 9: 213.
33. Rogawski MA, et al. *Pharmacological Rev*. 1990; 42: 223.
34. Bum NE, et al. *Fitoterapia*. 2004; 75: 309.
35. Poschel BPH. In *Handbook of Psychopharmacology*. Iversen LL, Iversen SD, Snyder SH, eds. New York: Plenum Press 1988, p437.
36. Lister RG, et al. *Pharmacol Pharmac Ther*. 1990; 46: 321.
37. File SE, et al. *Behav Brain Res*. 2001; 125: 151.
38. Mrugnandam AV, et al. *Ind J Pharmacol*. 2000; 32: S119.
39. Wielosz S, et al. *J Pharm Pharmacol*. 1979; 31:410.
40. Ichihara K, et al. *J Pharmacol Exp Ther*. 1993; 264: 122.
41. Arnsten AF, et al. *Neurobiol Aging*. 1997; 18: 21.
42. Barnes JM, et al. *Pharmacol Biochem Behav*. 1990; 53: 955.
43. Bhattacharya SK, et al. *Indian J Exp Biol*. 1989; 27: 261.
44. Samson A, et al. *J of Ethnopharmacol*. 2001; 78: 33.
45. Janssen PAJ, et al. *Int Rev Neurobiol*. 1965; 8: 221.
46. Drew GM, et al. *Br J Pharmacol*. 1977; 63: 468.
47. Hock FJ. In *Gene, brain and behavior*. Elsner N, Heisenberg M, eds. Proceeding of 21st Gottingen Neurobiology Conference. Stuttgart: George Thieme Verlag 1993, p681.
48. Hollander E, et al. *Br Med Bull*. 1986; 42:97.
49. Nalini K, et al. *J Ethnopharmacol*. 1995; 47:101.
50. Ogren SO. In, *Biology of Serotonergic Transmission*. Osborne NN, ed. Chichester: John Wiley and Sons 1982, p317.
51. White HS, et al. *Epilepsia*. 1997; 1(38): S9.
52. Loscher W, et al. *Epilepsy Res*. 1988; 3:145.